Mani Foroohar, an analyst from Leerink Partners, maintained the Buy rating on Crispr Therapeutics AG (CRSP – Research Report). The associated price target was lowered to $65.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Mani Foroohar has given his Buy rating due to a combination of factors including Crispr Therapeutics AG’s strategic developments and ongoing advancements in their pipeline. The company has made significant progress with its Casgevy product, achieving $10 million in sales for FY24 and expanding its global reach with over 50 authorized treatment centers.
Additionally, Crispr Therapeutics AG is actively progressing several promising therapies across different stages of development. These include updates expected in mid-2025 for CTX112 and in 2025 for CTX131, alongside a strategic partnership with Nkure Therapeutics for the co-development of CTX112 in India. The ongoing in vivo gene editing programs and early-stage assets further support the potential for future growth, justifying the Buy rating.
In another report released today, JMP Securities also maintained a Buy rating on the stock with a $86.00 price target.